Review



recombinant human soluble bmp receptor type 1a  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human soluble bmp receptor type 1a
    FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml <t>BMP-2</t> with or without 0.25 and 1.0 g/ml <t>sBMPR-1A</t> for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.
    Recombinant Human Soluble Bmp Receptor Type 1a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1135 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+soluble+bmp+receptor+type+1a/Recombinant+Human+BMP-4+Protein/10__1074_slash_jbc__m112__426080-52-10-36
    Average 97 stars, based on 1135 article reviews
    recombinant human soluble bmp receptor type 1a - by Bioz Stars, 2026-08
    97/100 stars

    Images

    1) Product Images from "Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity"

    Article Title: Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

    Journal: Journal of Biological Chemistry

    doi: 10.1074/jbc.m112.426080

    FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml BMP-2 with or without 0.25 and 1.0 g/ml sBMPR-1A for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.
    Figure Legend Snippet: FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml BMP-2 with or without 0.25 and 1.0 g/ml sBMPR-1A for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.

    Techniques Used: Cell Culture, Activity Assay, Western Blot



    Similar Products

    recombinant human soluble bmp receptor type 1a  (R&D Systems)
    97
    R&D Systems recombinant human soluble bmp receptor type 1a
    FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml <t>BMP-2</t> with or without 0.25 and 1.0 g/ml <t>sBMPR-1A</t> for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.
    Recombinant Human Soluble Bmp Receptor Type 1a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+soluble+bmp+receptor+type+1a/Recombinant+Human+BMP-4+Protein/10__1074_slash_jbc__m112__426080-52-10-36
    Average 97 stars, based on 1 article reviews
    recombinant human soluble bmp receptor type 1a - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml BMP-2 with or without 0.25 and 1.0 g/ml sBMPR-1A for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.

    Journal: Journal of Biological Chemistry

    Article Title: Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

    doi: 10.1074/jbc.m112.426080

    Figure Lengend Snippet: FIGURE 4. Participation of BMPs in W9 stimulation in E1 cells. A, E1 cells were cultured in the presence of 50 M W9 or 5 ng/ml BMP-2 with or without 0.25 and 1.0 g/ml sBMPR-1A for 5 days. ALP activity was measured by the pNPP method and expressed as the mean S.D. b, p 0.01 versus W9; d, p 0.01 versus BMP-2. Significant difference was determined using ANOVA with Dunnett’s test. B, postconfluent E1 cells were stimulated with 100 M W9 for 10–360 min, and each whole cell lysate was prepared from the cells using RIPA buffer. Phosphorylated Smad1/5/8, total Smad1, and -actin were detected by Western blotting. C, E1 cells were cultured in the presence or absence of 100 M W9 with or without 0.4 and 2.0 g/ml anti-BMP-2/4 neu- tralizing antibody (BMP-2/4) for 5 days. Data were measured as described above and expressed as the mean S.D. b, p 0.01 versus W9. Significant difference was determined using ANOVA with Dunnett’s test.

    Article Snippet: Recombinant human TNF- , recombinant human BMP-2, anti-BMP-2/4-neutralizing polyclonal antibody, recombinant human soluble BMP receptor type 1A (sBMPR1A), recombinant human TNF- , recombinant humanWnt5a, recombinant human Wnt10b, and recombinant mouse Dickkopf-related protein (Dkk-1) were purchased from R&D Systems (Minneapolis, MN).

    Techniques: Cell Culture, Activity Assay, Western Blot